Skip to main content

Month: January 2023

SLR Investment Corp. Announces Monthly Distribution for January 2023

NEW YORK, Jan. 10, 2023 (GLOBE NEWSWIRE) — SLR Investment Corp. (the “Company”) (NASDAQ: SLRC), today declared a distribution of $0.136667 per share for the month of January 2023. The distribution is payable on February 2, 2023 to stockholders of record as of January 26, 2023. The specific tax characteristics of the distribution will be reported to stockholders on Form 1099 after the end of the calendar year. ABOUT SLR INVESTMENT CORP. SLR Investment Corp. is a closed-end investment company that has elected to be treated as a business development company under the Investment Company Act of 1940. A specialty finance company with expertise in several niche markets, the Company generally invests directly and indirectly in leveraged, U. S. middle market companies primarily in the form of cash flow senior secured loans, including first...

Continue reading

Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea

Topline data expected in the first half of 2023 SCOTTSDALE, Ariz., Jan. 10, 2023 (GLOBE NEWSWIRE) — Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage biopharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that it has fully enrolled and randomized all of the patients in its Phase 3 clinical program to assess the safety, efficacy and tolerability of DFD-29 (Minocycline Modified Release Capsules 40 mg) for the treatment of papulopustular rosacea (“PPR”). The Phase 3 clinical trials are part of a collaboration with Dr. Reddy’s Laboratories Ltd. for the ongoing development and commercialization of the DFD-29 program. Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey...

Continue reading

BBSI Earns 2023 Great Place to Work Certification™

VANCOUVER, Wash., Jan. 10, 2023 (GLOBE NEWSWIRE) — Barrett Business Services, Inc. (BBSI) (NASDAQ: BBSI), a leading provider of business management solutions and one of the largest professional employer organizations (PEO) in the U.S., is proud to announce it has again been Certified™ by Great Place to Work®. The prestigious award is based entirely on what current employees say about their experience working at BBSI. Great Place to Work® is the global authority on workplace culture, employee experience, and the leadership behaviors proven to deliver market-leading revenue, employee retention and increased innovation. “Great Place to Work Certification™ isn’t something that comes easily – it takes ongoing dedication to the employee experience,” said Sarah Lewis-Kulin, Vice President of Global Recognition at Great Place...

Continue reading

Milestone Scientific Announces TEKMIKA as Exclusive STA Single Tooth Anesthesia System® Distributor in Brazil

ROSELAND, N.J., Jan. 10, 2023 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provides painless and precise injections, today announced it has entered into a distribution agreement granting TEKMIKA Health Technologies exclusive distribution rights to market Milestone’s STA Single Tooth Anesthesia System® (STA) in Brazil. TEKMIKA Health Technologies is a leading distributor in Brazil, focused on importing, promotion, marketing and distribution of high-tech medical equipment and devices. All digital marketing of the STA and disposables will be carried out through SUPREVIDA, utilizing a 100% digital, immersive ecosystem to support the sales team and customers. SUPREVIDA will also handle all aspects of service, as well as logistics and fulfillment. The STA...

Continue reading

iCoreConnect Launches a New Software With Concierge Service, iCoreVerify+

iCoreConnect Automated Insurance Verification Software With Concierge Service Helps Solve the Staffing Challenges Facing Dental Practices OCOEE, FL, Jan. 10, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – iCoreConnect, Inc., (OTCQB: ICCT), a Software-as-a-Service (SaaS) company with an enterprise and healthcare workflow platform, today announced the product launch of iCoreVerify+ a software and concierge service that expands the capabilities of its iCoreVerify automated insurance verification software.   iCoreVerify automated insurance verification software completes approximately 80% of the manual work required to verify a patient’s insurance. The remaining 20% of verifications require some manual checking due to the lack of participation from some insurance companies. iCoreVerify+ concierge service provides the solution for the ...

Continue reading

Paltalk to be Featured on Inaugural ClearThink IR Virtual Live Event on Wednesday, January 11, 2023 at 12 Noon ET

JERICHO, NY, Jan. 10, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Paltalk, Inc. (“Paltalk,” the “Company,” “we,” “our” or “us”) (Nasdaq: PALT), a communications software innovator that powers multimedia social applications, today announced that Chief Executive Officer Jason Katz will appear on ClearThink IR Virtual Live on Wednesday, January 11, 2023 at 12 noon ET. The inaugural ClearThink IR Virtual Live, powered by Paltalk, will be hosting a different CEO every Wednesday at 12 noon ET for a fire side chat followed by an engaging Q&A discussion. It’s a great opportunity to learn about the product offerings of an emerging growth micro-cap company. Please click on this link to sign up and install Paltalk to register for the ClearThink Capital IR room: https://invite.paltalk.net/ClearThinkCapital. Jason Katz, Chairman and CEO...

Continue reading

Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial

Tel Aviv, Israel / Vancouver, Canada, Jan. 10, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND) (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, announced that it has successfully manufactured batches of its drug candidate, MEAI-based molecule CMND-100, for use in its first in-human clinical trial. The trial will evaluate the psychedelic-derived drug candidate for the treatment of Alcohol Use Disorder (AUD).  “Having our drug candidate ready to be tested is a major milestone toward our first in-human clinical trial,” said Dr. Adi Zuloff-Shani, Clearmind’s Chief Executive Officer. “Our pre-clinical positive results indicated the potential of our unique treatment...

Continue reading

Grom Social Enterprises Issues Shareholder Letter and Provides Corporate Update

BOCA RATON, Fla, Jan. 10, 2023 (GLOBE NEWSWIRE) — Grom Social Enterprises, Inc. (NASDAQ: GROM) (“Grom” or the “Company”), a media, technology and entertainment company dedicated to family-friendly programming, web filtering technology and safe social media for kids, today issued a letter to shareholders from Darren Marks, its Chairman and Chief Executive Officer. Dear Fellow Shareholders, On behalf of our entire organization, we hope that you enjoyed a magical holiday season and we wish you all health, happiness, and success in the New Year. Fiscal 2022 was a foundational year for Grom as we fortified our core businesses to drive growth and future profitability. We remained steadfast to our values and primary objectives to provide safe, secure platforms and environments for kids to interact and explore; to deliver world class animation...

Continue reading

Exela Technologies Signs Strategic Partnership with Quintes Global

CHENNAI, India, Jan. 10, 2023 (GLOBE NEWSWIRE) — Exela Technologies, Inc. (“Exela”) (NASDAQ: XELA, XELAP), a global business process automation (“BPA”) leader, today announced a partnership with Quintes Global (“QG”), an innovative company with a differentiated first-of-its-kind offering of ‘Dedicated Captive Solutions’ headquartered in New Delhi, India. Exela will deploy its cloud-based Robotic Process Automation (“RPA”) solution, to enable end-to-end digitization of processes performed by QG for its customers under the unique Dedicated Captive Model. Exela provides an intuitive and fully customizable RPA solution that can be leveraged to create task-specific software bots that deploy best practices using big data, machine learning, artificial intelligence, natural language processing, and predictive analysis. The solution is...

Continue reading

Greystone Housing Impact Investors LP Announces Sales of Vantage at Stone Creek and Vantage at Coventry

OMAHA, Neb., Jan. 10, 2023 (GLOBE NEWSWIRE) — Greystone Housing Impact Investors LP (NYSE: GHI) (the “Partnership”) announced today that on January 5, 2023, Vantage at Stone Creek and Vantage at Coventry, each being a 294-unit market rate multifamily property located in Omaha, NE, were sold at the direction of the respective managing members. The Partnership’s investment in Vantage at Stone Creek was originated in March 2018 and the Partnership contributed equity totaling $7.1 million during construction. The Partnership’s investment in Vantage at Coventry was originated in September 2018 and the Partnership contributed equity totaling $8.1 million during construction. As a result of the sales, the Partnership’s equity investment in each property was redeemed. At closing of the sales, the Partnership received net cash of approximately...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.